Ebvallo (tabelecleucel)

EBV+ PTLD ยท Oncology (PTLD)

FDA approved 2024 Orphan designation EMA approved MHRA approved Accessible via NPP

Ask about Ebvallo

Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.

We reply on WhatsApp.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

About Ebvallo

Ebvallo (tabelecleucel) is a allogeneic t-cell manufactured by Pierre Fabre/Atara, used in the treatment of EBV+ PTLD. It received FDA approval in 2024 under the Traditional pathway.

Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.

Accessing Ebvallo through Reserve Meds

We help patients in the Middle East, India, Pakistan, Africa, and other regions access Ebvallo via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.

What we need from you

  • A prescription from a licensed physician in your country of residence.
  • A clinical justification from the prescribing physician (why Ebvallo for this patient).
  • Destination-country NPP or personal-import paperwork (we help prepare these).
  • Patient consent for cross-border drug import under the applicable pathway.

Typical timeline

We give you a written timeline estimate for your case before you commit. Timing varies by destination country regulatory review speed and physician documentation turnaround.

Indication context

Ebvallo is indicated for EBV+ PTLD. The condition falls within Oncology (PTLD). For patients with this condition in countries where Ebvallo is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.

About the manufacturer

Ebvallo is manufactured by Pierre Fabre/Atara. We source drug supply exclusively through a US-licensed pharmaceutical wholesale partner, ensuring every unit is authentic, serialized, and chain-of-custody documented.

International regulatory status

  • United States: FDA approved (2024).
  • EMA (EU): Approved.
  • MHRA (UK): Approved.
  • Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.

Start a request for Ebvallo

If you or a family member needs Ebvallo and it is not available in your country, submit a request. Our clinical team will review eligibility and reach out within one business day.

Ask about a medicine Or message us on WhatsApp

Ebvallo, country access pages

Information on how patients in different countries access Ebvallo through Named Patient Program pathways.

  • Ebvallo in United Arab Emirates, The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
  • Ebvallo in Saudi Arabia, The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
  • Ebvallo in India, India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
  • Ebvallo in Kuwait, Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
  • Ebvallo in Qatar, Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
  • Ebvallo in Bahrain, Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.

Safety, interactions, and handling

Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.

Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.

Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.

Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at pv@reservemeds.com. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.

Last medically reviewed: 2026-04-22 (see Trust & Compliance).

Access by country

Reserve Meds publishes a detailed country deep-dive for Ebvallo in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Frequently asked questions

How can I get Ebvallo if it is not approved or available in my country?

Reserve Meds coordinates US-sourced Ebvallo for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.

Can I access Ebvallo through a named-patient import?

Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ebvallo. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.

Do I need a prescription to access Ebvallo through Reserve Meds?

Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.

How does Reserve Meds deliver Ebvallo to a patient?

Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ebvallo to your treating physician or hospital pharmacy, with appropriate handling for the product.

How long does it take, and what does Ebvallo cost through Reserve Meds?

After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.

How do I start a request for Ebvallo?

Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.

Review & oversight. Content on this page is reviewed by the Reserve Meds clinical operations team. Your treating doctor's prescription is verified before anything ships. Regulatory information on this site is general information, not legal advice. Review methodology ›
Last medically reviewed: .
WhatsApp